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22 Abstract 
23 Endometrial cancer is a common gynaeological malignancy: life time exposure to oestrogen is 
24 a key risk factor. Oestrogen action is mediated by receptors encoded by ESR1 (ERα) and 
25 ESR2 (ERβ): ERα plays a key role in regulating endometrial cell proliferation. A truncated 
26 splice variant isoform (ERβ5) encoded by ESR2 is highly expressed in cancers. This study 
27 explored whether ERβ5 alters oestrogen responsiveness of endometrial epithelial cells.  
28 Immunhistochemistry profiling of human endometrial cancer tissue biopsies identified 
29 epithelial cells co-expressing ERβ5 and ERα in stage I endometrial adenocarcinomas and post 
30 menopausal endometrium.  Induced co-expression of ERβ5 in ERαpos endometrial cancer cells 
31 (Ishikawa) significantly increased ligand-dependent activation of an ERE-luciferase reporter 
32 stimulated by either E2 or the ERα-selective agonist 1,3,5-(4-Hydroxyphenyl)-4-Propyl-1H-
33 pyrazole (PPT) compared to untransfected cells. Fluorescence recovery after photobleaching 
34 (FRAP) analysis of tagged yellow fluorescent protein (YFP)-ERβ5 transfected into Ishikawa 
35 cells revealed that incubation with E2 induced a transient reduction in intra-nuclear mobility 
36 characterised by punctate protein redistribution which phenocopied the behaviour of ERα 
37 following ligand activation with E2. In ERαneg MDA-MD-231 breast cancer cells there was 
38 no E2-dependent change in mobility of YFP-ERβ5 and no activation of the ERE reporter in 
39 cells expressing ERβ5.
40 In conclusion, we demonstrate that ERβ5 can act as heterodimeric partner to ERα in Ishikawa 
41 cells and increases their sensitivity to E2. We speculate that expression of ERβ5 in 
42 endometrial epithelial cells may increase the risk of malignant transformation and suggest that 
43 immunostaining for ERβ5 should be included in diagnostic assessment of women with early 
44 grade cancers. 
45
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46 Introduction 
47 Endometrial cancer is the most common gynaecological malignancy in the developed world 
48 with the majority presenting as abnormal bleeding in post-menopausal women; the incidence 
49 of this cancer is increasing in parallel with changing demographics characterized by an aging 
50 population and increased prevalence of obesity (Sanderson, et al. 2017). Clinically, 
51 endometrial cancers are routinely classified as having a type I or type II phenotype, with the 
52 former being oestrogen-dependent and the latter oestrogen-independent (Bokhman 1983). 
53 A study examining the risk factors for type I and type II endometrial cancers based on 14,069 
54 cancer cases, reported that risk of developing either type of malignancy was influenced by 
55 parity, oral contraceptive use, age at menarche, and diabetes but higher BMI had a greater 
56 effect on the risk of developing a type I tumour (Setiawan, et al. 2013).  A genome wide-
57 significant association between endometrial cancer and a CYP19A1 (aromatase gene) SNP 
58 associated with increased circulating E2 concentrations has been reported (Thompson, et al. 
59 2016).  In pre-menopausal women the primary source of endogenous oestrogens are the 
60 ovaries although local biosynthesis can also occur in the endometrium (Gibson, et al. 2013; 
61 Gibson and Saunders 2012). After menopause synthesis of oestrogens in non-ovarian sites 
62 such as adipose tissue predominates but expression of oestrogen biosynthetic enzymes 
63 including CYP19A1, HSD17B1 and sulfatase within endometrial cancer tissues is consistent 
64 with intracrine biosynthesis of bioactive oestrogens from blood borne steroid precursors. For 
65 example sulfatase converts of E1-S to E1, and HSD17B1 can convert E1 to E2  (reviewed in 
66 (Rizner, et al. 2017; Sinreih, et al. 2017)). 
67 Oestrogenic ligands (endogenous or synthetic) can induce phenotypic changes that can 
68 contribute to increased cancer risk including proliferation, angiogenesis, migration and 
69 epithelial to mesenchymal transition by binding to oestrogen receptors which act as ligand-
70 activated transcription factors.  In women the key nuclear oestrogen receptors are ERα, 
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71 encoded by ESR1, and ERβ encoded by ESR2: both receptors are expressed in endometrial 
72 tissue during the normal menstrual cycle (Critchley, et al. 2002). Studies using knockout mice 
73 have highlighted the importance of Esr1 in mediating the proliferative effects of oestrogens 
74 on endometrial epithelial cells (Winuthayanon, et al. 2017). A study of ~6000 cancer patients, 
75 reported a strong risk signal for endometrioid cancers was located in a promoter of ESR1 
76 (O'Mara, et al. 2015). 
77 In common with other members of the nuclear receptor family (van der Vaart and Schaaf 
78 2009), the ESR1 and ESR2 genes are subject to alternative splicing with both C terminal and 
79 exon-skipping isoforms identified in cancer cell lines and human tissues including the testis 
80 (Saunders, et al. 2002). In this paper we have focused on a C-terminal splice variant of ESR2 
81 called ERβ5 which contains an indentical sequence encoded by exons 1-7 of the wild type 
82 protein (sometimes called ERβ1 to distinguish it from variant isoforms) but incorporates a 
83 unique 8th exon. The resultant protein has an intact DNA binding domain but lacks amino 
84 acids in the E/F domains of ERβ1 which contribute to the ligand binding pocket and binding 
85 of co-factors critical for a robust response to ligand (Gibson and Saunders 2012; Poola, et al. 
86 2005). This splice variant does not exist in rodents.  We have previously developed a specific 
87 antibody to the unique C-terminus of the protein and confirmed expression in endometrial and 
88 other cancers (Collins, et al. 2009; Shaaban, et al. 2008; Wong, et al. 2005). Despite lacking 
89 an intact ligand binding domain, cell line studies have reported that co-expression of ERβ5 
90 can have alter transcriptional activity of ERs in response to oestrogens. For example, in COS7 
91 cells (SV40 transformed monkey kidney cells) ERβ5 was able to bind DNA in a gel shift 
92 assay and inhibited the activity of ERα, but not ERβ1, on a TGF-beta3-CAT gene reporter 
93 (Peng, et al. 2003; Poola et al. 2005). In HEK293 (embryonic kidney) cells ERβ1:ERβ5 
94 heterodimers induced greater expression of an ERE reporter gene in response to incubation 
95 with E2 but ERα co-transfection was not tested (Leung, et al. 2006). Overexpression of ERβ5 
Page 4 of 45Accepted Manuscript published as ERC-19-0291.R2. Accepted for publication: 27-Nov-2019
Copyright © 2019 Society for Endocrinology Downloaded from Bioscientifica.com at 12/06/2019 01:53:35PM
via University of Edinburgh
ERbeta5 and endometrial cancer 
5
96 in PC3 cells (metastatic, ERβpos, prostate cancer cells) increased cell migration (Leung, et al. 
97 2010). Taken together these results suggest that expression of ERβ5 can have an impact on 
98 oestrogen-responsiveness and therefore has the potential to alter oestrogen-driven progression 
99 of malignancy in cancers, albeit in a cell-context dependent manner.
100 In support of this, some reports suggest immunoexpression of ERβ5 could be a useful 
101 prognostic indicator in cancer. Wimberley et al (Wimberly, et al. 2014) reported 
102 immunoexpression of ERβ5 was associated with worse outcome in triple negative/HER-2 
103 breast cancer patients. In a study on prostate cancer cytoplasmic ERβ5 staining was 
104 associated with a reduced survival time to post-operative metastases (Leung et al. 2010). 
105 Over-expression of ERβ5 has also been reported in colon cancers (Wong et al. 2005), glioma 
106 (Li, et al. 2013), cancers of the ovary (Ciucci, et al. 2014) and of the thymus (Li, et al. 2015) 
107 however to date the impact of ERβ5 in endometrial cancers is unknown.
108 In this study we have demonstrated co-expression with of ERβ5 with ERα in epithelial 
109 cell nuclei of stage I endometrial adenocarcinomas and provided novel evidence to support 
110 formation of ERα:ERβ5 heterodimers in cell line model of endometrial adenocarcinom 
111 (Ishikawa). These results suggest the presence of ERβ5 in ERα positive cells may augment 
112 the oestrogen-sensitivity of cells and drive malignant transformation.
113
114 Materials and Methods
115 Patients and tissue collection
116 Endometrial adenocarcinomas had previously been recovered from post-menopausal women 
117 (n=101) undergoing total abdominal hysterectomy. Written informed consent was obtained 
118 from all patients and ethical approval granted by the Lothian Research Ethics committee 
119 (LRE 1999/6/4) as detailed in (Collins et al. 2009). Additional (control) samples (n=9) were 
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120 obtained from women who were postmenopausal (14 months to 26 years after their self-
121 reported last menstrual period) and attending clinics for treatment of benign gynaecological 
122 conditions, including heavy menstrual bleeding. In all cases women were recruited by 
123 dedicated research nurses and written consent was obtained prior to tissue collection under 
124 Research ethics 10/S1402/59 or 07/S1103/29. Tissue for immunohistochemistry was fixed in 
125 4% neutral buffered formalin overnight at 4oC. Tissue for RNA extraction was collected in 
126 RNALater (Qiagen). All cancers were confined to the uterus (stage I). Grading of tissues as 
127 well (G1), moderately (G2) or poorly differentiated (G3), was performed by an expert 
128 gynaecological pathologist according to the FIGO (International Federation of Obstetrics and 
129 Gynaecology) grading system (Scully, et al. 1994). We have previously used a subset of 
130 samples from this tissue archive and conducted DAB immunohistochemistry to investigate 
131 immunoexpression of individual ESR2-encoded proteins (Collins et al. 2009). 
132 Cell lines 
133 Endometrial epithelial adenocarcinoma Ishikawa cells were originally derived from a well 
134 differentiated adenocarcinoma in a 39 year old pre-menopausal woman (Nishida, et al. 1985): 
135 catalogue no 99040201, (ECACC, Wiltshire, UK). RL95-2 endometrial epithelial carcinoma 
136 cells derived from a moderately differentiated 64yr old, catalogue no RL95-2 ATCC-CRL-
137 1671 (LGC Standards, Middlesex, UK). MFE-280 endometrial epithelial adenocarcinoma 
138 cells derived from a poorly differentiated endometrial carcinoma from a 78yr old, catalogue 
139 no ECACC-98050131 (Public Health England, Salisbury, UK) p68, Lot no 11J030.  The 
140 human MDA-MB-231 breast adenocarcinoma cell line was originally isolated from pleural 
141 effusions of a Caucasian 51-year old breast cancer patient (ECACC catalogue no. 92020424). 
142 The source and authentication of cell lines are described in Supplementary Table 1 using the 
143 ICLAC cell line checklist as a template.
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144 Cells were maintained at 37oC, 5% CO2 in DMEM supplemented with 1% non-essential 
145 amino acids, 2mM L-glutamine, 105U/L penicillin, 100mg/L streptomycin, 1.25g/l fungizone 
146 and 10% heat inactivated fetal bovine serum (FBS). For experiments, cells were grown for 
147 48h in phenol red free DMEM supplemented with 10% charcoal stripped FBS (CSFBS). 
148 Previous studies in our laboratory had established that the MDA-MB-231 cells did not contain 
149 either mRNA or protein encoded by ESR1, whereas the Ishikawa cells used in this study 
150 contained both ERα mRNA and protein (Collins et al. 2009). Comparison of Ishikawa RL95-
151 2 and MFE endometrial cancer cells revealed that endogenous expression of ERα could only 
152 be detected in the Ishikawa cells where it was approximately 1:1 with ERβ5 (Supplementary 
153 Figure 2): failure to detect ERα in the other cells would be consistent with loss of expression 
154 in less differentiated cancer cells (see Collins et al. 2009).
155 Transient transfections to establish cell lines expressing different receptor ratios
156 Adenoviral constructs expressing full length ERα, ERβ1 and ERβ5 cDNAs were prepared as 
157 described previously (Bombail, et al. 2010). In order to generate proteins with fluorescent 
158 protein tags for FRAP analysis (see below) full length cDNAs encoding human ERα and 
159 ERβ5 were subcloned between the Eco RI and Bam HI restriction sites in plasmid vectors 
160 expressing yellow fluorescent protein (pEYFP-C1) or cyan fluorescent protein expression 
161 vector (pECFP-C1) (Clontech (Mountain View, CA, USA). Inserts (YFP/CFP-receptor) were 
162 subcloned into the pDC315 shuttle vector (Microbix) recombined into the adenoviral genome 
163 (pBHGLOx deltaE1, Cre, Microbix) and used to generate high titre stocks as previously 
164 described (Bombail et al. 2010). To generate an Ad-ERE-Luc reporter the cDNA from a 
165 plasmid construct containing a 3xERE-tk-luciferase reporter gene that was a kind gift from 
166 Professor DP McDonnell (Hall, 1999), Duke University NC, USA) was sub-cloned into an 
167 adenoviral vector and particles purified as described above (Bombail et al. 2010).
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168 To establish cells with expression of ERα, ERβ1 and ERβ5 MDA-MD-231 and Ishikawa cells 
169 were plated at 1x105 cells/ml in phenol red free DMEM with 10% CSFCS for 24h prior to 
170 infection with adenovirus expressing each receptor at multiplicity of infection (MOI) of 50 for 
171 4h before replacing the media with serum free DMEM. The cells were cultured for 24h for 
172 RNA expression and 48h for protein expression. To establish Ishikawa cells with an ERβ5 > 
173 ERα ratio adenovirus expressing ERβ5 was used at a MOI of 75 and ER was knocked down 
174 using a Silencer Select Predesigned siRNA (Ambion/Life). Cells were seeded at 1x105 
175 cells/ml and grown to 60-70% confluence before being transfected with lipofectamine 
176 RNAiMAX (Life) and 15pmol of siRNA per well. Cells were incubated for 48h for mRNA 
177 expression and 72h for protein expression. Cells were stimulated with vehicle control 
178 (ethanol), E2 10-8M (Sigma) or 10-8M of the ER-selective agonist PPT (4,4',4''-(4-Propyl-
179 [1H]-pyrazole-1,3,5-triyl)trisphenol, Tocris. (Meyers, et al. 2001) for 8h
180 RNA extraction and Taqman quantitative RT-PCR
181 RNA extraction from tissues or cells was performed as described in (Collins et al. 2009): 
182 RNA concentration and purity was measured using the Nanodrop (LabTech International, 
183 Lewes, UK) and standardised to 100ng/µl for all samples. Reverse transcription was 
184 performed using 100ng of RNA with 0.125x Superscript Enzyme in 1x VILO reaction mix 
185 (Life, Paisley, UK) at 25oC for 10 min, followed by 42oC for 60 min and finally 85oC for 5 
186 min. Quantitative PCR was performed using probes for genes of interest from the Universal 
187 Probe Library (Roche Diagnostics, Burgess Hill, UK) and specific primers as detailed in 
188 (Collins et al. 2009).
189 Double Fluorescent Immunohistochemistry on tissue sections
190 Tissue sections were subjected to antigen retrieval in citrate buffer pH6 and processed 
191 according to standard laboratory protocols. Sections were first incubated with mouse 
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192 monoclonal ERβ5 (clone 5/25. BioRad, cat no. MCA4676T) diluted 1:200 in normal goat 
193 serum (NGS) overnight at 4oC, followed by goat anti-mouse peroxidase fab (Abcam) 1:500 in 
194 serum for 30 min at room temperature and finally incubated with Tyramide Fluorescein 
195 (PerkinElmer, Cambridgeshire, UK) at 1:50 in kit diluent for 10 min. Antibody elution was 
196 carried out by boiling sections in citrate buffer for 2.5 min followed by 30 min rest, incubated 
197 in NGS for 30 min at RT, blocked by Streptavidin/biotin following manufacturer’s 
198 instructions (Vector, Peterborough, UK). Sections were washed and incubated with ERα 
199 mouse monoclonal (Vector, Cat no. VP-E614) at 1:80 in NGS overnight at 4oC. Slides were 
200 incubated with goat anti-mouse biotinylated (Abcam) at 1:500 in serum for 30 min at RT, 
201 followed by Streptavidin Alexa fluor 546 (Molecular Probes, Paisley, UK) 1:200 in PBS for 
202 1h. Sections were washed, counterstained with DAPI (Sigma, Poole, UK) at 1:1000 in PBS 
203 for 10 min before finally mounting in Permafluor (PerkinElmer). All washes between 
204 antibodies were carried out 3 times in TBS. Full details of antibodies used in the study are 
205 provided in Supplementary Table 2. 
206 Luciferase reporter assays. 
207 The first set of experiments consisted of Ishikawa and MDA-MD-231 cells (either uninfected) 
208 or infected with adenovirus containing constructs for ERα or ERβ5 alone, or both ERα and 
209 ERβ5 at MOI of 50.  In a second set of experiments Ishikawa cells were stably infected with 
210 ERβ5 at MOI of 75 (to overexpress ERβ5) or transfected with a siRNA specific for ERα 
211 (using reagents in siERα assay ID s4824 silencer select, Invitrogen) allowing the functional 
212 impact of different ratios of ERα to ERβ5 to be examined. In both experiments cells were 
213 plated at 1x105 cells /ml in 24 well tissue culture plates in DMEM with 10%  CSFBS and 
214 cultured for 24h before infection with Ad-ERE-Luc vector at MOI of 50; media was 
215 replenished after 4h. Cells were incubated for 24h prior to treatment with vehicle control 
216 (ethanol), E2 10-8M (Sigma, Poole, UK) or PPT 10-8M (Tocris). Luciferase activities were 
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217 determined using Bright-Glo luciferase reagents according to the manufacturer’s instructions 
218 (Promega). 
219 Fluorescence Recovery after Photobleaching (FRAP). 
220 Cells cultured on 35mm cover slips in 60mm plates (Mat-Tek) at 1 x 105 cells/ml were 
221 infected with each of the viral constructs (MOI 50) for 24h prior to live cell imaging. Cells 
222 were maintained in 2.5% HEPES/PBS solution on a heated stage at 37°C. Only cells with 
223 relatively low levels of fluorescence were used in the FRAP experiment to avoid problems 
224 associated with overexpression and the bulk averaging of large numbers of nuclei.
225 FRAP was conducted using a Zeiss LSM 510 laser scanning confocal microscope. Images 
226 were captured in a 256 X by 100 Y frame through 63X objective lens before and after ligand 
227 treatment at 3sec intervals for up to 30sec after bleaching. Bleaching was carried out on a 
228 single z-section of the chosen cell (ROI I) with excitation of the Argon 12 laser (488 and 
229 514nm) and emission via the 530-600 band pass yellow filter. The pinhole was kept open to 
230 the maximum and the number of iterations kept at 100. The fluorescence intensity data was 
231 normalised for each cell and used for in a non-linear regression model, Y=Ymax x (1-e-Kx) 
232 (GraphPad Prism 4), where the regression coefficient r2 was typically 0.95. The Ymax and 
233 half-life of recovery values (0.69/K) were averaged for at least 20 cells per treatment.
234 Statistical Analysis of FRAP measurements. 
235 The bleached area was designated Region of Interest I (ROI I). A second unbleached region in 
236 the same cell (ROI II) was used to normalise the bleached area. A third region (ROI III) was 
237 chosen outside the nucleus of interest to ensure the bleaching effect was focused on ROI I 
238 only. Fluorescence intensity of the bleached region over the time course of scans were 
239 normalised against those of ROI II to account for the differences in immunofluorescent levels 
240 throughout the cell nucleus. All scanned images post-bleach were normalised against the pre-
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241 bleached state to derive the percentage recovery (and to allow for differences in actual 
242 strength of bleaching between cells). The first image post-bleach was subsequently 
243 normalised to 0 and recovery rates defined against this value. Variability between cells was 
244 resolved by normalising time at bleaching to 0 and successive scan times measured against 
245 this. A non-linear regression curve fit was carried out on the resultant figures. This generated 
246 the values of YMAX (maximum level of recovery at which values reach a plateau) and Half-
247 time (time taken in seconds to reach half of the YMAX). Unpaired t-tests of the regression 
248 statistics were carried out to compare these between the treated versus ligand stimulated cells. 
249 Significant differences were noted as those with P ≤ 0.05.
250 Results
251 ERβ5 mRNA and protein are expressed in both normal endometrium and endometrial 
252 adenocarcinomas
253 Messenger RNAs for both ERα and ERβ5 were detected in endometrial samples from post-
254 menopausal women (PMC, 9, Figure 1 A, B). Expression levels of ERα mRNA were 
255 significantly lower in cancers graded as G1 well-defined (p<0.01), G2 moderately defined 
256 (p<0.01) or G3 poorly defined (p<0.001) than in PMC (Figure 1A). ERβ5 mRNA expression 
257 appeared to be higher in the cancers than the PMC tissue although the wide variation between 
258 patients meant this did not reach statistical significance (Figure 1B). These findings extend 
259 those previously reported on a subset of 30 of these 101 endometrial cancer samples (Collins 
260 et al. 2009).  
261 Immunoflourescent co-staining of ERß5 and ERα identified epithelial cells which express 
262 both proteins in type I endometrial cancers.
263 Fluorescent co-staining with antibodies specific for ERα or ERβ5 identified cells expressing 
264 one (green, red) or both (yellow/orange) proteins in stage I endometrial cancers (Figure 2). In 
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265 samples of well- and moderately- differentiated cancers there was a well-defined epithelial 
266 layer surrounding gland-like structures (G) which had intense immunostaining for ERβ5 
267 (green nuclei, Figure 2. A-C), but within the stroma there were cells that appeared to express 
268 ERα (red) alone (fibroblast-like shape) (Figure 2. A-C). In samples with a more disorganised 
269 tissue architecture (Figure 2. D-F) there was no distinct gland structure but coexpression of 
270 ERβ5 and ERα was readily detected (yellow/orange cell nuclei). When the green (ERβ5) and 
271 red (ERα) channels were separated it was apparent that the intensity of immunostaining for 
272 ERα in epithelial cells was variable whereas ERβ5 appeared more uniform resulting in 
273 variable ratios of ERα:ERβ5 in individual epithelial nuclei (Figure 3). 
274 In endometrium from postmenopausal women both ERα and ERβ5 proteins were detected 
275 with evidence of co-expression in some epithelial cells lining the glands whereas those lining 
276 the lumen appeared to lack ERα (Supplementary Figure 1).
277 ERβ5 enhances E2-dependent activation of an ERE reporter gene
278 To investigate if ERβ5 expression altered oestrogen responsiveness, two cell lines were used: 
279 endometrial Ishikawa cells that contained both ERβ5 and ERα mRNAs (ratio ~1:1) and 
280 MDA-MB-231 breast cancer cells which were ERα negative and had only very low levels of 
281 endogenous ERβ5 mRNA (Supplementary Figure 3). Like MDA-MB-231 two endometrial 
282 cancer cell lines (RL92-2, MFE) that were evaluated also lacked endogenous ERα mRNAs 
283 but had much higher concentrations of ERβ5 which made then unsuitable for the transfection 
284 study. In addition to these wild-type cell lines transfections of each cell line were undertaken 
285 using adenoviral vectors containing ERα (Ad-ERα) or ERβ5 (Ad-ERβ5) alone or in 
286 combination. In response to treatment with E2, or the ERα-selective agonist PPT (Meyers et 
287 al. 2001), wild-type Ishikawa cells significantly increased expression of a luciferase reporter 
288 gene under the control of an ERE response element compared to vehicle (Figure 4A). 
289 Tranfection with Ad-ERβ5 significantly increased luciferase expression in response to E2 
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290 (Figure 4A) or PPT (Figure 4B) compared with wild-type cells or those transfected with Ad-
291 ERα (Figure 4B). Co-transfection of cells with Ad-ERα+AdERβ5 did not increase expression 
292 of luciferase in the Ishikawa cells beyond that of the cells infected with ERβ5 alone in 
293 response to E2 (Figure 4A) and appeared to blunt the response to PPT (Figure 4B). In line 
294 with expectations, MDA-MD-231 cells did not upregulate expression of the ERE-luc reporter 
295 in response to E2 or PPT unless they were infected with Ad-ERα either alone or in 
296 combination with Ad-ERβ5 (Figure 4C, D). In contrast to Ishikawa cells transfection with 
297 Ad-ERβ5 had no impact on expression of the ERE-luc reporter consistent with MDA-MD-
298 231 cells lacking endogenous ERα (Figure 4 C, D).
299 To extend these studies ERE reporter activation in Ishikawa cells that expressed three 
300 different ratios of mRNAs encoded by the receptors were compared: a) wildtype cells ~1:1 
301 ratio (ERα:ERβ5), b) cells infected with Ad-ERβ5 (ratio ERβ5:ERα ~1.5:1), c) cells depleted 
302 of ERα using siRNA-mediated knockdown (ERβ5:ERα ~2.5:1). Protein knockdown resulting 
303 in reduced expression of ERα were confirmed by Western blot (Supplementary Figure 4).  
304 Consistent with earlier findings wild type cells and those with enhanced expression of ERβ5 
305 both increased expression of the ERE-luc reporter in response to E2 with a significant 
306 increase in the Ad-ERβ5 cells compared to wild-type (Figure 5). The importance of ERα was 
307 confirmed by siRNA knockdown and by incubation of the cells with the anti-oestrogen ICI 
308 (Figure 5).  
309 FRAP analysis of YFP-ERβ5 reveals altered mobility in response to E2 in Ishikawa cells
310 As ERE reporter studies suggested that ERβ5 could alter transcriptional activity in Ishikawa 
311 cells when co-expressed with ERα, further experiments were performed to explore whether 
312 this was associated with formation of ERα/ERβ5 hetero-dimers.
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313 Live cell imaging and FRAP was used to explore the dynamics of YFP-tagged ERβ5 in the 
314 nuclei of ERαpos Ishikawa and ERαneg MDA-MD-231 cells using established methods 
315 (Bombail et al. 2010).  Follwing transfection of Ishikawa cells with the majoirty of YFP-
316 ERβ5 protein being detected in the nuclear compartment in line with expectations FRAP 
317 analysis revealed that in cells treated with DMSO (vehicle control) this protein was highly 
318 mobile (Figure 6 C, D). Addition of E2 resulted in changes in the appearance of some but not 
319 all cell nuclei.  In one population of cells where there was no evidence of altered mobility in 
320 response to E2 (Figure 6 A, C) but in second population of cells incubation with E2 induced a 
321 rapid reduction in intra-nuclear receptor mobility and adoption of a ‘punctate’ distribution 
322 (Figure 6 B, D). Further detailed analysis of the latter revealed that the punctate appearance 
323 was both rapid and transient, peaking ~20 minutes after introduction of E2 (Figure 6. E, F). 
324 Mobility of YFP-ERβ5 in MDA-MD-231 cells was not altered by treatment with E2 even 
325 when cells were co-transfected with ERα (Supplementary Figure 5): these results are 
326 consistent with the results obtained using the ERE-luciferase reporter.
327 Discussion 
328 Life-time exposure to oestrogens, treatment with drugs with oestrogenic activity, exposure to 
329 endocrine disruptors, or oestrogen exposure unopposed by progesterone (for example during 
330 the peri-menopause) have all been implicated in rising rates of endometrial cancer (reviewed 
331 in (Rizner et al. 2017; Sanderson et al. 2017).  
332 In contrast to the limited data on ERβ5 a large number of publications have suggested that 
333 ERβ1, the full length ESR2 isoform which has an intact ligand binding pocket, acts as a 
334 negative modulator of ERα in breast and other cancer cells (Chang, et al. 2006)(Zhao, et al. 
335 2007). A systematic review of evidence from immunohistochemical studies of breast cancers 
336 concluded that the positive association between ERβ1 expression and 5-year overall survival 
337 was only evident in ERα positive patients (Liu, et al. 2016). Structural analyses also suggest 
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338 ERαβ heterodimers are more stable than ERββ homodimers and conservation of peptides 
339 implicated in the heterodimeric interaction in ERβ5 are consistent with historical gel shift 
340 studies reporting this variant can dimerise (Chakraborty, et al. 2012; Poola et al. 2005). In a 
341 study using single chain ERs to explore the relative contributions of ERα and ERβ1 to 
342 heterodimer activities Li et al (Li, et al. 2004) reported ERα is the functionally dominant 
343 partner in ERα/ERβ1 heterodimers. The results of the current study appear to be in agreement 
344 with this observation with binding of ligand to ERα essential to the activation of reporter 
345 constructs. 
346 Our studies in endometrial cancer tissue are in agreement with other results reporting 
347 expression of ERβ5 protein is upregulated in a number of hormone-responsive cancers 
348 compared with equivalent non malignant tissues (Li et al. 2015). Smith et al identified 
349 different exons (E0K, E0N) in the 5’UTR sequences of ESR2 transcripts (Smith, et al. 2010) 
350 and showed that the translational efficiency of a GFP reporter gene was higher when the 
351 promoter contained the E0N exon sequence. They highlighted the importance of translational 
352 regulation in determining expression levels of ESR2 variants, including ERβ5, in breast 
353 cancer cell lines (Smith et al. 2010). They also speculated that overexpression of eIF4E could 
354 explain an increase in the translational efficiency ESR2 variants such as ERβ5 in cancer. 
355 Although it would be intersting determine which 5’UTR drives expression of ERβ5 variant 
356 mRNAs in endometrium and whether this is altered in endometrial cancers this was outside 
357 the scope of the current investigation.
358 In this study we have, for the first time, demonstrated that ERα and ERβ5 proteins are co-
359 expressed in endometrial adenocarcinomas with evidence that most epithelial cells in stage I 
360 cancers were immunopositive for ERβ5 but with variable expression of ERα. These results 
361 are in agreement with previous findings obtained using a subset of the current samples and 
362 single colour staining (see figure 2 in (Collins et al. 2009). A paper by Haring and colleagues 
Page 15 of 45 Accepted Manuscript published as ERC-19-0291.R2. Accepted for publication: 27-Nov-2019
Copyright © 2019 Society for Endocrinology Downloaded from Bioscientifica.com at 12/06/2019 01:53:35PM
via University of Edinburgh
ERbeta5 and endometrial cancer 
16
363 (Haring, et al. 2012) has reported that the ratio of ERβ5:ERα mRNA rises in parallel with 
364 grade.
365 As ERβ5 protein is clearly expressed in some endometrial cancers in a pattern that overlaps 
366 with that of ERα we used a variety of cell-based methods to explore whether this might alter 
367 the response of cells to E2. Studies were conducted in Ishikawa cells which expressed 
368 endogenous ERα as well as MDA-MD-231 cells which had no native ERα: significant 
369 differences in the impact of overexpression of ERβ5 in these cell backgrounds were apparent 
370 when their oestrogen-responsiveness was assessed using a reporter gene under the control of 
371 an ERE promoter. In the Ishikawa cells overexpression of ERβ5 resulted in a significant 
372 increase in reporter gene activity in response to either E2 or PPT, an ERα-selective agonist. 
373 Further studies using siRNAs confirmed that activation of the reporter gene was ERα-
374 dependent. In contrast in MDA-MD-231 cells there was no induction of the ERE reporter in 
375 wild type cells or those transfected with Ad-ERβ5. A key question arising from these studies 
376 was how does ERβ5 increase ERα-dependent ERE activation even though the protein is 
377 unable to bind E2? One possible explaination is that it stabilises a conformation of ERα that 
378 favours co-activator recruitment. In this study we showed that the ratio between the different 
379 receptors makes a difference to activation of the ERE reporter in Ishikawa cells with a ratio of 
380 ERβ5:ERα mRNAs of between 1:1 and 1.5:1 able to enhance reporter responses. In MDA-
381 MD-231 cells co-expression of ERβ5 with ERα did not enhance response to E2 or PPT above 
382 that of ERα alone. It has been reported that ERβ5 can inhibit ERα-dependent activation of an 
383 ERE reporter gene in COS7 cells (Peng et al. 2003).  Older papers have also reported that 
384 greater ratios of ERβ5 (10:1 ERα) resulted in reduced expression of ERα (Poola et al. 2005). 
385 These contrasting results suggest cell context (availability of cofactors?) as well as the ratios 
386 of ER subtypes can alter oestrogen responsiveness but still need to be repeated in a wider 
387 range of cell types to validate this hypothesis
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388 Reporter gene activation is a useful and widely employed read-out of oestrogen response but 
389 FRAP is a more powerful tool as it allows for monitoring the mobility of receptor proteins in 
390 real time in individual cells.  The Mancini group have published a number of elegant studies 
391 documenting intranuclear dynamics of fluorescent-tagged ERα protein (Stenoien, et al. 2000; 
392 Stenoien, et al. 2001a; Stenoien, et al. 2001b). They showed that in the absence of steroid 
393 ligand ERα is highly mobile within the nuclear environment and that addition of E2 results in 
394 reduced mobility which they suggest reflects enhanced interactions with immobile nuclear 
395 proteins (Stenoien et al. 2001b). In the current study we report novel evidence that the intra-
396 nuclear mobility of YFP-tagged ERβ5 was altered in response to E2 in Ishikawa cells. The 
397 time frame of the immobilisation and recovery of the YFP-ERβ5 mirrored that of tagged ERα 
398 constructs used in our own and other studies including the redistribution into a ‘punctate’ 
399 pattern. ERβ5 lacks amino acids corresponding to Helix 12 in the wild-type ERβ1 protein. It 
400 has been reported that these sequences are required for ligand-dependent immobilisation of 
401 ERα (Stenoien et al. 2001b) hence the formation of a heterodimer with ligand-activated ERα 
402 is the most likely mechanism by which this change in ERβ5 mobility is occurring. Notably, in 
403 the current study, not all Ishikawa cells transfected with YFP-ERβ5 showed altered 
404 intranuclear mobility in response to E2. Immunostaining of cells from cultures of Ishikawa 
405 cells used in this study with anti-ERα antibodies (data not shown) revealed variable 
406 expression of ERα leading us to conclude reduced mobility of YFP-ERβ5 in E2 treated cells 
407 is restricted to those cells that are ERαpos. We also noted parallels between these results and 
408 those of a previous study using Ishikawa cells in which we detected changes in intranuclear 
409 mobility of an FP-tagged construct of an orphan member of the nuclear receptor superfamily 
410 ERRβ which like ERβ5 lacks an intact ligand binding domain (Bombail et al. 2010). 
411 We also performed some experiments using MDA-MD-231 breast cancer cells which lacked 
412 endogenous ERα. Notably, whilst a change in nuclear mobility of YFP-ERα was detected in 
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413 response to E2 co-transfection of YFP-ERβ5 and ERα did not result in altered mobility of the 
414 YFP-ERβ5 receptor and we speculate that this cell environment did not favour formation of 
415 stable heterodimers (see supplementary Figure 3). These results highlight the importance of 
416 using cells with a phenotype that is close to the disease under consideration. 
417 ERβ5 may also have roles in cancer that are independent of ERα.  The sequence of the protein 
418 contains an intact N terminal domain containing amino acids might be susceptible to 
419 phosphorylation by growth factor dependent pathways resulting in steroid ligand-independent 
420 activation. This has not been tested but may provide a mechanistic explanation as to why 
421 expression of ERβ5 is associated with worse outcomes in HER2-positive and triple-negative 
422 patients (Wimberly et al. 2014) and can have an impact on response to chemotherapeutic 
423 agent induced apoptosis (Lee, et al. 2013). 
424 Recent efforts to expand our understanding of disease progression have used molecular rather 
425 than morphological criteria to define subtypes of endometrial cancers. For example, The 
426 Cancer Genome Atlas (TCGA) identified four major endometrial cancer groups (1-4): POLE 
427 mutations, microsatellite instability, copy-number low/microsatellite stable, and copy-number 
428 high/‘serous-like (Cancer Genome Atlas Research, et al. 2013). Notably in this analysis the 
429 authors identified three robust clusters termed ‘mitotic’, ‘immunoreactive’ and ‘hormonal’ 
430 based on their RNA analysis with the hormonal subgroup being comprised of endometrioid 
431 grade 1/2 tissues exhibiting upregulation of hormone responsive genes including ESR1 and 
432 PR (Cancer Genome Atlas Research et al. 2013). In future studies it would be interesting to 
433 see whether upregulated expression of ESR2 (including ERβ5) is also associated with this 
434 cluster.
435 In summary, our results provide novel evidence that expression of ERβ5 may increase 
436 oestrogen responsiveness of ERαpos in some endometrial cancer cells by forming ERβ5-ERα 
437 heterodimers. A limitation of our study is that only one endometrial cancer cell line was used 
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438 as other lines tested lacked endogenous ERα hence generalisation of the findings to all 
439 endometrial cancers requires investigation in other cells as well as integration with the latest 
440 genomic datasets.  We suggest that expression of ERβ5 should be considered in risk 
441 assessment of women with early grade endometrial cancer as this may inform therapeutic 
442 strategies. 
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579 Figure Legends
580 Figure 1. Detection of mRNAs for ERα and ERβ5 in endometrial cancers.
581 Expression of ERα/ERβ5 mRNA is altered in women with endometrial cancer compared to 
582 post menopausal controls (PMCs). Expression of ERα mRNA (A) and ERβ5 mRNA (B) in 
583 PMCs (n=9), G1 well differentiated (n=19), G2 moderately differentiated (n=52) and G3 
584 poorly differentiated (n=30). Total RNA for ERα in G1, G2, and G3 (p<0.0001) were 
585 significantly lower than PMCs. Expression of ERβ5 mRNA appeared to increase in G3 
586 compared to PMC but did not reach significance. Results are expressed as fold difference 
587 compared to PMCs with statistical analysis performed by one way anova with Tukey’s post 
588 hoc test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
589
590 Figure 2. Co-localisation of ERα and ERβ5 in stage 1 endometrial adenocarcinomas identifies 
591 variable co-expression of both proteins in a subset of epithelial cells. 
592 Examples of staining in endometrial cancer tissues classified by a pathologist as G1 well (A, 
593 B), G2 moderately (C, D) or G3 poorly (E, F) differentiated. Note glands (G) surrounded by a 
594 single layer of epithelial cells could be identified in well and some moderately differentiated 
595 tissue associated with a stromal compartment (S) containing fibroblasts (s). The architecture 
596 of the poorly differentiated cancers less organised and dominated by epithelial cells. Intense 
597 immunostaining for ERβ5 (green, asterisks) as well as evidence of co-expression of ERα 
598 (yellow-red, arrows) was detected in epithelial cells.
599
600 Figure 3. Confocal imaging identifed epithelial cells in endometrial cancers with variable 
601 amounts of ERα and ERβ5 proteins.
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602 Confocal images typical of endometrial cancers classified as well or moderately differentiated 
603 are illustrated showing merged (top panel) and individual channels for ERβ5 (green, middle) 
604 and ERα (lower red). The intensity of immunostaining for ERβ5 appeared similar between 
605 different nuclei within each of these samples whereas the amount of protein in nuclei stained 
606 with an antibody specific for ERα (red) revealed a range of intensities from low to high with 
607 the latter identifed by yellow/orange staining in the merged image (examples * and 
608 arrowhead). Scale bars 50µm.
609
610 Figure 4. Impact of ERβ5 on expression of an ERE-luciferase reporter gene in Ishikawa and 
611 MDA-MD-231 cells. 
612 Over expression of ERβ5 significantly increased the ERE-luciferase activity in response to E2 
613 (*** p<0.001) and PPT (*p<0.05) in Ishikawa cells (A, B).  Increased expression of the 
614 reporter response to E2 (C) or PPT (D) was detected in MDA-MD-231 cells transfected with 
615 ERα (**** p<0.0001) but not with ERβ5 alone. The number of replicates ranged from a 
616 minimum of 4 on triplicate wells and statistical analysis was performed by one way anova 
617 with Tukey’s post hoc test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
618
619 Figure 5. ERα plays a critical role in E2-dependent reporter gene activity in Ishikawa cells 
620 expressing ERβ5. 
621 Overexpression of ERβ5 in ERαpos Ishikawa cells (ratio mRNAs ERβ5: ERα = 1.5:1) resulted 
622 in a significant increase in reporter gene compared to cells treated with vehicle (24h +/-E2). 
623 Targeted knockdown of ERα abrogated response to E2.  Results are displayed as fold 
624 difference compared to vehicle: triplicate experiments performed in triplicate wells. Statistical 
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625 analysis performed by one way anova with Tukey’s post hoc test, *p<0.05, **p<0.01, 
626 ***p<0.001, ****p<0.0001. 
627
628 Figure 6. FRAP analysis of YFP-tagged ERβ5 in Ishikawa identifies a population of cells 
629 with altered nuclear mobility of ERβ5 in response to E2.
630 Following incubation of ERαpos, YFP-ERβ5 Ishikawa cells with E2 two populations of cells 
631 were identified: A) cells in which YFP-tagged ERβ5 was uniformly distributed within the 
632 nucleus apart from the nucleolus (dark circles) and B) cells in which YFP protein was not 
633 uniform but appeared to be concentrated in selected regions (hereafter refered to as ‘punctate). 
634 Using the software of the confocal it was possible to determine the mobility of YFP protein 
635 within a bleached region of interest (ROI): protein in A cells remained highly mobile 
636 regardless of the presence of ligand whereas in B cells addition of E2 resulted in a rapid 
637 reduction in mobility. Further analysis of the population of cells exhibiting altered mobility 
638 (E, F) revealed that the change in mobility following addition of E2 was time-dependent with 
639 the highest percentage of punctate cells at 30 minutes (F). A minimum of 9 to a maximum of 
640 16  individual cells were examined. 
641
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Figure 1. Detection of mRNAs for ERα and ERβ5 in endometrial cancers.Expression of ERα/ERβ5 mRNA is 
altered in women with endometrial cancer compared to post menopausal controls (PMCs). Expression of ERα 
mRNA (A) and ERβ5 mRNA (B) in PMCs (n=9), G1 well differentiated (n=19), G2 moderately differentiated 
(n=52) and G3 poorly differentiated (n=30). Total RNA for ERα in G1, G2, and G3 (p<0.0001) were 
significantly lower than PMCs. Expression of ERβ5 mRNA appeared to increase in G3 compared to PMC but 
did not reach significance. Results are expressed as fold difference compared to PMCs with statistical 
analysis performed by one way anova with Tukey’s post hoc test, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
193x94mm (300 x 300 DPI) 
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Figure 2. Co-localisation of ERα and ERβ5 in stage 1 endometrial adenocarcinomas identifies variable co-
expression of both proteins in a subset of epithelial cells. 
Examples of staining in endometrial cancer tissues classified by a pathologist as G1 well (A, B), G2 
moderately (C, D) or G3 poorly (E, F) differentiated. Note glands (G) surrounded by a single layer of 
epithelial cells could be identified in well and some moderately differentiated tissue associated with a 
stromal compartment (S) containing fibroblasts (s). The architecture of the poorly differentiated cancers less 
organised and dominated by epithelial cells. Intense immunostaining for ERβ5 (green, asterisks) as well as 
evidence of co-expression of ERα (yellow-red, arrows) was detected in epithelial cells. 
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Figure 3. Confocal imaging identifed epithelial cells in endometrial cancers with variable amounts of ERα and 
ERβ5 proteins. 
Confocal images typical of endometrial cancers classified as well or moderately differentiated are illustrated 
showing merged (top panel) and individual channels for ERβ5 (green, middle) and ERα (lower red). The 
intensity of immunostaining for ERβ5 appeared similar between different nuclei within each of these samples 
whereas the amount of protein in nuclei stained with an antibody specific for ERα (red) revealed a range of 
intensities from low to high with the latter identifed by yellow/orange staining in the merged image 
(examples * and arrowhead). Scale bars 50µm. 
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Figure 4. Impact of ERβ5 on expression of an ERE-luciferase reporter gene in Ishikawa and MDA-MD-231 
cells. Over expression of ERβ5 significantly increased the ERE-luciferase activity in response to E2 (*** 
p<0.001) and PPT (*p<0.05) in Ishikawa cells (A, B).  Increased expression of the reporter response to E2 
(C) or PPT (D) was detected in MDA-MD-231 cells transfected with ERα (**** p<0.0001) but not with ERβ5 
alone. The number of replicates is depicted on each graph and statistical analysis was performed by one way 
anova with Tukey’s post hoc test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
208x201mm (300 x 300 DPI) 
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Figure 5. ERα plays a critical role in E2-dependent reporter gene activity in Ishikawa cells expressing ERβ5. 
Overexpression of ERβ5 in ERαpos Ishikawa cells (ratio mRNAs ERβ5: ERα = 1.5:1) resulted in a significant 
increase in reporter gene compared to cells treated with vehicle (24h +/-E2). Targeted knockdown of ERα 
abrogated response to E2.  Results are displayed as fold difference compared to vehicle: triplicate 
experiments performed in triplicate wells. Statistical analysis performed by one way anova with Tukey’s post 
hoc test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
166x75mm (300 x 300 DPI) 
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Figure 6. FRAP analysis of YFP-tagged ERβ5 in Ishikawa identifies a population of cells with altered nuclear 
mobility of ERβ5 in response to E2.Following incubation of ERαpos, YFP-ERβ5 Ishikawa cells with E2 two 
populations of cells were identified: A) cells in which YFP-tagged ERβ5 was uniformly distributed within the 
nucleus apart from the nucleolus (dark circles) and B) cells in which YFP protein was not uniform but 
appeared to be concentrated in selected regions (hereafter refered to as ‘punctate). Using the software of 
the confocal it was possible to determine the mobility of YFP protein within a bleached region of interest 
(ROI): protein in A cells remained highly mobile regardless of the presence of ligand whereas in B cells 
addition of E2 resulted in a rapid reduction in mobility. Further analysis of the population of cells exhibiting 
altered mobility (E, F) revealed that the change in mobility following addition of E2 was time-dependent with 
the highest percentage of punctate cells at 30 minutes (F). A minimum of 9 to a maximum of 16 individual 
cells were examined 
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Cell Line Checklist for Manuscripts and Grant Applications
This checklist is a resource for scientists who write or review manuscripts and/or for grant applications 
that use cell lines.  Cross-contaminated cell lines could give unreliable results if used for research 
because they no longer correspond to the reported donor tissue and so may not represent the correct 
species, tissue type or disease state.  Such misidentified or false cell lines produce unreliable 
research data and we urge reviewers to highlight their use wherever possible.
This checklist will help the author or reviewer to look for obvious cell line quality concerns.  The 
checklist may also be used to communicate any quality concerns to be addressed prior to publication 
or funding.
Manuscript or Grant Information
Title or Manuscript/Grant ID: ERb5 increases oestrogen responsiveness of Era positive endometrial cancer cells 
Cell Lines used:
Ishikawa: Human endometrial adenocarcinoma, 
ECACC 99040201
MDA-MB-231 Human breast adenocarcinoma
ECACC 92020424
RL95: Human endometrial epithelial cancer 
ATCC CRL-1671
MFE-280: Human endometrial epithelial 
adenocarcinoma
ECACC 98050131
Cell Lines used with Quality Concerns:
Cell Line Information
Reporting Requirement Indicate “Yes” or “No” (No includes Not Known)Add further comment if required
Cell line is known to be 
cross-contaminated or 
otherwise misidentified:
See the ICLAC website for a 
register of known misidentified 
cell lines and 
Recommendation 1) below.
NO
Authentication testing has 
been performed:
The method and results 
should be listed.  
See Recommendation 2) 
below.
Authentication of Ishikawa and MDA-MB-231was performed by STR 
analysis (see attached method and results) 
RL95 and MFE-280authenticated by Eurofins (Ebersberg, Germany) 
using PCR-single-locus-technology
Human cell lines:  STR 
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Mycoplasma testing has 
been performed:
The method and results 
should be listed.
Mycoalert TM Mycoplasma Detection Kit (Lonza, LT07-118). 
Absorbance read on CLARIOstar Plus (BMG Labtech)
Positive and negative controls included with each test. Cells 
routinely tested every 6 months.
A ratio above 1 indicates mycoplasma positive.
Table below is representative of results routinely detected.












P36 115 46 0.4 Negative
Ishikawa P17 91 67 0.736 Negative
MDA-
MB-231
P40 68 32 0.471 Negative
Ishikawa P21 120 68 0.567 Negative
RL95 P68 176 108 0.614 Negative
MFE-
280
P72 138 120 0.870 Negative
Positive 
control
106 2439 23.01 Positive
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Negative 
control
163 17 0.104 Negative
Source for cell line is listed:
The catalogue number should 
be included if obtained from a 
cell line repository.
See Recommendation 3) 
below.
Ishikawa: Human endometrial adenocarcinoma, ECACC 99040201
MDA-MB-231 Human breast adenocarcinoma
ECACC 92020424
RL95: Human endometrial epithelial cancer 
ATCC CRL-1671
MFE-280: Human endometrial epithelial adenocarcinoma
ECACC 98050131
RRID Number for cell line is 
listed:
The Resource Identification 
Initiative (RRID) is meant to 
help researchers cite the 
important resources used in 
scientific papers.






Sufficient information is 
given to replicate 
experiments using the cell 
line:






Cells passaged a maximum of 10 times 
Recommendations
1) ICLAC recommends that false cell lines (misidentified cell lines with no known authentic stock) 
should not be used.  ICLAC’s register of misidentified cell lines can be found at 
http://iclac.org/databases/cross-contaminations. 
2) ICLAC recommends that authentication testing should always be performed on established cell 
lines regardless of the application; the test method and results should be included in the 
Materials and Methods section.  Testing should be done, at minimum, at the beginning and end 
of experimental work.  
For human cell lines, short tandem repeat (STR) profiling should be performed and compared to 
results from donor tissue, or to online databases of human cell line STR reference profiles.
More information can be found in the published Standard:  ANSI/ATCC ASN-0002-2011 
Authentication of Human Cell Lines: Standardization of STR Profiling.  ANSI eStandard Store.
For non-human cell lines, best practice will vary with the species being tested.  At minimum, 
species should be confirmed using an appropriate method such as karyotyping, isoenzyme 
analysis, or mitochondrial DNA typing (DNA barcoding).
More information on authentication testing can be found at http://iclac.org/references/.
3) It will be helpful for the reader if authors can include a reference, to provide more information on 
the cell line’s establishment and characterization.  However, not all cell lines have this 
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information available in the public domain.
4) Cell line RRIDs are assigned through a collaboration between Cellosaurus and the Resource 
Identification Initiative. RRIDs can be found by searching for cell lines at 
https://web.expasy.org/cellosaurus/ 
5) This information may include the growth medium used, including additives; any additional growth 
requirements, including special substrates and gas mixtures; and the passage number or 
population doubling level (PDL) used for experimental work.
Passage number is important when working with early passage or finite cultures, or cell lines 
where changes in phenotype have been documented with increasing passage.  ICLAC 
recommends that laboratories freeze down stocks when they first receive a cell line and set a 
limit (e.g. 20 passages) to avoid overpassaging.  More information can be found at
http://iclac.org/resources/advice-scientists/ 
Notes or Further Comments 
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Supplier/Cat number Target Species raised, 
monoclonal/polyclonal










of the full length 
alpha form of the 
human estrogen 
receptor molecule.










derived from the C-
terminus of human 
ERB5
Mouse Monoclonal Colorectal cancer 1:200 √
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Supplementary Figure legends
Supplementary Figure 1. Immunoexpression of ERβ5 and ERα in postmenopausal 
endometrium. 
Immunostaining identified glandular epithelial cells in postmenopausal endometrium 
that co-expressed ERβ5 and ERα in (orange/yellow, asterisks) associated with the 
glands (G). Notably epithelial cells lining the lumen appeared to be predominantly 
immunopositive for ERβ5 (green). Cells within the stroma were a mixture of 
immunonegative (blue), ERβ5 positive and ERβ5/ERα double positive.
Supplementary Figure 2. Expression of ERα and ERβ5 mRNAs in endometrial cancer 
cell lines. Expression of ERα (A) and ERβ5 (B) mRNAs in Ishikawa, RL95 and MFE 
cells. N= 3 per sample with triplicate. Note endogenous ERα mRNAs were only 
detectable in Ishikawa cells. 
Supplementary Figure 3. Comparison between Ishikawa and MDA-MB-231cells. 
Note MDA-MB-231 do not contain quantifiable ERα. N=8-10 per sample with 
triplicate wells.
Supplementary Figure 4. Protein expression in Ishikawa cells in which ratios of ERα 
and ERβ5 were manipulated using a pool of siRNAs directed against ERα or 
lentivirus containing ERβ5. Results were generated by quantification on Western 
blots using STAT1 as a loading control. N=3 for each condition. 
Supplementary Figure 5. FRAP analysis of YFP-tagged ERs in MDA breast cancer 
cells 
Individual MDA-MB-231 cells infected with adenovirus expressing full length YPF-
tagged ERα (A, positive control); (B) YFP-ERβ5 (C) YFP-ERβ5 plus and untagged 
ERα; Cells were treated with vehicle alone (DMSO) or vehicle containing E2 10-8M. 
Note analysis of % Recovery of fluorescence after bleaching the ROI identified a 
significant decrease in nuclear mobility of YFP only in cells infected with ERα-YFP 
whereas ERβ5-YFP remained highly mobile even when exogenous ERα was 
introduced into the cells suggesting the cellular context of these cells did not 
support/sustain hetero-dimerisation.
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